Evaluating DAPK as a therapeutic target

Apoptosis

Volumn 19, Issue 2, 2014, Pages 371-386

  Huang, Yide ^a   Chen, Ling ^a   Guo, Libin ^a   Hupp, Ted R ^b   Lin, Yao ^a  

^a FUJIAN NORMAL UNIVERSITY   (China)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

DAPK; Kinase inhibitor; Therapeutic target

Indexed keywords

ANIMALS; BRAIN DISEASES; CELL DEATH; DEATH-ASSOCIATED PROTEIN KINASES; ENZYME ACTIVATORS; ENZYME INHIBITORS; HUMANS; INFLAMMATION; MOLECULAR TARGETED THERAPY; NEOPLASMS; NEURONS;

EID: 84894972613     PISSN: 13608185     EISSN: 1573675X     Source Type: Journal    
DOI: 10.1007/s10495-013-0919-2     Document Type: Review

References (203)

1. Chen XP, Du GH (2007) Target validation: a door to drug discovery. Drug Discov Ther 1(1):23-29
2. Overington JP, Al-Lazikani B, Hopkins AL (2006) How many drug targets are there? Nat Rev Drug Discov 5(12):993-996
3. Pennisi E (2012) Genomics. ENCODE project writes eulogy for junk DNA. Science 337(6099):1159-1161
4. Baker NM, Der CJ (2013) Cancer: drug for an 'undruggable' protein. Nature 497(7451):577-578
5. Bialik S, Kimchi A (2006) The death-associated protein kinases: structure, function, and beyond. Annu Rev Biochem 75:189-210
6. Michie AM, McCaig AM, Nakagawa R, Vukovic M (2010) Death-associated protein kinase (DAPK) and signal transduction: regulation in cancer. FEBS J 277(1):74-80
7. Tu W, Xu X, Peng L, Zhong X, Zhang W, Soundarapandian MM, Balel C, Wang M, Jia N, Lew F, Chan SL, Chen Y, Lu Y (2010) DAPK1 interaction with NMDA receptor NR2B subunits mediates brain damage in stroke. Cell 140(2):222-234
8. Chakilam S, Gandesiri M, Rau TT, Agaimy A, Vijayalakshmi M, Ivanovska J, Wirtz RM, Schulze-Luehrmann J, Benderska N, Wittkopf N, Chellappan A, Ruemmele P, Vieth M, Rave-Frank M, Christiansen H, Hartmann A, Neufert C, Atreya R, Becker C, Steinberg P, Schneider-Stock R (2013) Death-associated protein kinase controls STAT3 activity in intestinal epithelial cells. Am J Pathol 182(3):1005-1020
9. Nakav S, Cohen S, Feigelson SW, Bialik S, Shoseyov D, Kimchi A, Alon R (2012) Tumor suppressor death-associated protein kinase attenuates inflammatory responses in the lung. Am J Respir Cell Mol Biol 46(3):313-322
10. Luo XJ, Li W, Yang LF, Yu XF, Xiao LB, Tang M, Dong X, Deng QP, Bode AM, Liu JK, Cao Y (2011) DAPK1 mediates the G1 phase arrest in human nasopharyngeal carcinoma cells induced by grifolin, a potential antitumor natural product. Eur J Pharmacol 670(2-3):427-434
11. Deiss LP, Feinstein E, Berissi H, Cohen O, Kimchi A (1995) Identification of a novel serine/threonine kinase and a novel 15-kD protein as potential mediators of the gamma interferon-induced cell death. Genes Dev 9(1):15-30
12. Inbal B, Cohen O, Polak-Charcon S, Kopolovic J, Vadai E, Eisenbach L, Kimchi A (1997) DAP kinase links the control of apoptosis to metastasis. Nature 390(6656):180-184
13. Raveh T, Droguett G, Horwitz MS, DePinho RA, Kimchi A (2001) DAP kinase activates a p19ARF/p53-mediated apoptotic checkpoint to suppress oncogenic transformation. Nat Cell Biol 3(1):1-7
14. Bialik S, Kimchi A (2004) DAP-kinase as a target for drug design in cancer and diseases associated with accelerated cell death. Semin Cancer Biol 14(4):283-294
15. Wang WJ, Kuo JC, Yao CC, Chen RH (2002) DAP-kinase induces apoptosis by suppressing integrin activity and disrupting matrix survival signals. J Cell Biol 159(1):169-179
16. Kuo JC, Wang WJ, Yao CC, Wu PR, Chen RH (2006) The tumor suppressor DAPK inhibits cell motility by blocking the integrin-mediated polarity pathway. J cell biol 172(4):619-631
17. Mor I, Carlessi R, Ast T, Feinstein E, Kimchi A (2012) Death-associated protein kinase increases glycolytic rate through binding and activation of pyruvate kinase. Oncogene 31(6):683-693
18. Olivier M, Hollstein M, Hainaut P (2010) TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol 2(1):a001008
19. Katzenellenbogen RA, Baylin SB, Herman JG (1999) Hypermethylation of the DAP-kinase CpG island is a common alteration in B-cell malignancies. Blood 93(12):4347-4353
20. Simpson DJ, Clayton RN, Farrell WE (2002) Preferential loss of death associated protein kinase expression in invasive pituitary tumours is associated with either CpG island methylation or homozygous deletion. Oncogene 21(8):1217-1224
21. Kawaguchi K, Oda Y, Saito T, Yamamoto H, Takahira T, Tamiya S, Iwamoto Y, Tsuneyoshi M (2004) Death-associated protein kinase (DAP kinase) alteration in soft tissue leiomyosarcoma: promoter methylation or homozygous deletion is associated with a loss of DAP kinase expression. Hum Pathol 35(10):1266-1271
22. Toyooka S, Toyooka KO, Miyajima K, Reddy JL, Toyota M, Sathyanarayana UG, Padar A, Tockman MS, Lam S, Shivapurkar N, Gazdar AF (2003) Epigenetic down-regulation of death-associated protein kinase in lung cancers. Clin Cancer Res 9(8):3034-3041
23. Jin Y, Blue EK, Dixon S, Hou L, Wysolmerski RB, Gallagher PJ (2001) Identification of a new form of death-associated protein kinase that promotes cell survival. J Biol Chem 276(43):39667-39678
24. Lin Y, Stevens C, Harrison B, Pathuri S, Amin E, Hupp TR (2009) The alternative splice variant of DAPK-1, s-DAPK-1, induces proteasome-independent DAPK-1 destabilization. Mol Cell Biochem 328(1-2):101-107
25. Khoury MP, Bourdon JC (2011) p53 Isoforms: an intracellular microprocessor? Genes Cancer 2(4):453-465
26. Stevens C, Lin Y, Harrison B, Burch L, Ridgway RA, Sansom O, Hupp T (2009) Peptide combinatorial libraries identify TSC2 as a death-associated protein kinase (DAPK) death domain-binding protein and reveal a stimulatory role for DAPK in mTORC1 signaling. J Biol Chem 284(1):334-344
27. Tanaka T, Bai T, Yukawa K (2010) Death-associated protein kinase is essential for the survival of various types of uterine cancer cells. Int J Oncol 37(4):1017-1022
28. Tanaka T, Bai T, Yukawa K (2010) Suppressed protein expression of the death-associated protein kinase enhances 5-fluorouracil-sensitivity but not etoposide-sensitivity in human endometrial adenocarcinoma cells. Oncol Rep 24(5):1401-1405
29. Tanaka T, Bai T, Yukawa K (2011) Specific downregulation of death-associated protein kinase enhances Fas-mediated apoptosis in the human differentiated endometrial adenocarcinoma cell line HHUA. Eur J Gynaecol Oncol 32(3):293-296
30. Henshall DC, Araki T, Schindler CK, Shinoda S, Lan JQ, Simon RP (2003) Expression of death-associated protein kinase and recruitment to the tumor necrosis factor signaling pathway following brief seizures. J Neurochem 86(5):1260-1270
31. Schumacher AM, Velentza AV, Watterson DM, Wainwright MS (2002) DAPK catalytic activity in the hippocampus increases during the recovery phase in an animal model of brain hypoxic-ischemic injury. Biochim Biophys Acta 1600(1-2):128-137
32. Shamloo M, Soriano L, Wieloch T, Nikolich K, Urfer R, Oksenberg D (2005) Death-associated protein kinase is activated by dephosphorylation in response to cerebral ischemia. J Biol Chem 280(51):42290-42299
33. Pelled D, Raveh T, Riebeling C, Fridkin M, Berissi H, Futerman AH, Kimchi A (2002) Death-associated protein (DAP) kinase plays a central role in ceramide-induced apoptosis in cultured hippocampal neurons. J Biol Chem 277(3):1957-1961
34. Yamamoto M, Hioki T, Ishii T, Nakajima-Iijima S, Uchino S (2002) DAP kinase activity is critical for C(2)-ceramide-induced apoptosis in PC12 cells. Eur J Biochem 269(1):139-147
35. Henshall DC, Schindler CK, So NK, Lan JQ, Meller R, Simon RP (2004) Death-associated protein kinase expression in human temporal lobe epilepsy. Ann Neurol 55(4):485-494
36. Li Y, Grupe A, Rowland C, Nowotny P, Kauwe JS, Smemo S, Hinrichs A, Tacey K, Toombs TA, Kwok S, Catanese J, White TJ, Maxwell TJ, Hollingworth P, Abraham R, Rubinsztein DC, Brayne C, De Wavrant Vrieze F, Hardy J, O'Donovan M, Lovestone S, Morris JC, Thal LJ, Owen M, Williams J, Goate A (2006) DAPK1 variants are associated with Alzheimer's disease and allele-specific expression. Hum Mol Genet 15(17):2560-2568
37. Wu ZC, Zhang W, Yu JT, Zhang Q, Tian Y, Lu RC, Yu NN, Chi ZF, Tan L (2011) Association of DAPK1 genetic variations with Alzheimer's disease in Han Chinese. Brain Res 1374:129-133
38. Minster RL, DeKosky ST, Kamboh MI (2009) No association of DAPK1 and ABCA2 SNPs on chromosome 9 with Alzheimer's disease. Neurobiol Aging 30(11):1890-1891
39. Schjeide BM, McQueen MB, Mullin K, DiVito J, Hogan MF, Parkinson M, Hooli B, Lange C, Blacker D, Tanzi RE, Bertram L (2009) Assessment of Alzheimer's disease case-control associations using family-based methods. Neurogenetics 10(1):19-25
40. Tedde A, Piaceri I, Bagnoli S, Lucenteforte E, Piacentini S, Sorbi S, Nacmias B (2012) DAPK1 is associated with FTD and not with Alzheimer's disease. J Alzheimer's Dis 32(1):13-17
41. Hainsworth AH, Allsopp RC, Jim A, Potter JF, Lowe J, Talbot CJ, Prettyman RJ (2010) Death-associated protein kinase (DAPK1) in cerebral cortex of late-onset Alzheimer's disease patients and aged controls. Neuropathol Appl Neurobiol 36(1):17-24
42. Dachsel JC, Wider C, Vilarino-Guell C, Aasly JO, Rajput A, Rajput AH, Lynch T, Craig D, Krygowska-Wajs A, Jasinska-Myga B, Opala G, Barcikowska M, Czyzewski K, Wu RM, Heckman MG, Uitti RJ, Wszolek ZK, Farrer MJ, Ross OA (2011) Death-associated protein kinase 1 variation and Parkinson's disease. Eur J Neurol 18(8):1090-1093
43. Yamamoto M, Takahashi H, Nakamura T, Hioki T, Nagayama S, Ooashi N, Sun X, Ishii T, Kudo Y, Nakajima-Iijima S, Kimchi A, Uchino S (1999) Developmental changes in distribution of death-associated protein kinase mRNAs. J Neurosci Res 58(5):674-683
44. Chuang YT, Lin YC, Lin KH, Chou TF, Kuo WC, Yang KT, Wu PR, Chen RH, Kimchi A, Lai MZ (2011) Tumor suppressor death-associated protein kinase is required for full IL-1beta production. Blood 117(3):960-970
45. Mukhopadhyay R, Ray PS, Arif A, Brady AK, Kinter M, Fox PL (2008) DAPK-ZIPK-L13a axis constitutes a negative-feedback module regulating inflammatory gene expression. Mol Cell 32(3):371-382
46. Chuang YT, Fang LW, Lin-Feng MH, Chen RH, Lai MZ (2008) The tumor suppressor death-associated protein kinase targets to TCR-stimulated NF-kappa B activation. J Immunol 180(5):3238-3249
47. Kuester D, Guenther T, Biesold S, Hartmann A, Bataille F, Ruemmele P, Peters B, Meyer F, Schubert D, Bohr UR, Malfertheiner P, Lippert H, Silver AR, Roessner A, Schneider-Stock R (2010) Aberrant methylation of DAPK in long-standing ulcerative colitis and ulcerative colitis-associated carcinoma. Pathol Res Pract 206(9):616-624
48. Gandesiri M, Chakilam S, Ivanovska J, Benderska N, Ocker M, Di Fazio P, Feoktistova M, Gali-Muhtasib H, Rave-Frank M, Prante O, Christiansen H, Leverkus M, Hartmann A, Schneider-Stock R (2012) DAPK plays an important role in panobinostat-induced autophagy and commits cells to apoptosis under autophagy deficient conditions. Apoptosis 17(12):1300-1315
49. Martinet W, Schrijvers DM, De Meyer GR, Thielemans J, Knaapen MW, Herman AG, Kockx MM (2002) Gene expression profiling of apoptosis-related genes in human atherosclerosis: upregulation of death-associated protein kinase. Arterioscler Thromb Vasc Biol 22(12):2023-2029
50. Rennier K, Ji JY (2012) Shear stress regulates expression of death-associated protein kinase in suppressing TNFalpha-induced endothelial apoptosis. J Cell Physiol 227(6):2398-2411
51. Rennier K, Ji JY (2013) Effect of shear stress and substrate on endothelial DAPK expression, caspase activity, and apoptosis. BMC Res Notes 6:10
52. Okamoto M, Takayama K, Shimizu T, Ishida K, Takahashi O, Furuya T (2009) Identification of death-associated protein kinases inhibitors using structure-based virtual screening. J Med Chem 52(22):7323-7327
53. Okamoto M, Takayama K, Shimizu T, Muroya A, Furuya T (2010) Structure-activity relationship of novel DAPK inhibitors identified by structure-based virtual screening. Bioorg Med Chem 18(7):2728-2734
54. Velentza AV, Wainwright MS, Zasadzki M, Mirzoeva S, Schumacher AM, Haiech J, Focia PJ, Egli M, Watterson DM (2003) An aminopyridazine-based inhibitor of a pro-apoptotic protein kinase attenuates hypoxia-ischemia induced acute brain injury. Bioorg Med Chem Lett 13(20):3465-3470
55. Cho EY, Lee SJ, Nam KW, Shin J, Oh KB, Kim KH, Mar W (2010) Amelioration of oxygen and glucose deprivation-induced neuronal death by chloroform fraction of bay leaves (Laurus nobilis). Biosci Biotechnol Biochem 74(10):2029-2035
56. Wu B, Yao H, Wang S, Xu R (2013) DAPK1 modulates a curcumin-induced G2/M arrest and apoptosis by regulating STAT3, NF-kappaB, and caspase-3 activation. Biochem Biophys Res Commun 434(1):75-80
57. Carlessi R, Levin-Salomon V, Ciprut S, Bialik S, Berissi H, Albeck S, Peleg Y, Kimchi A (2011) GTP binding to the ROC domain of DAP-kinase regulates its function through intramolecular signalling. EMBO Rep 12(9):917-923
58. Lin Y, Henderson P, Pettersson S, Satsangi J, Hupp T, Stevens C (2011) Tuberous sclerosis-2 (TSC2) regulates the stability of death-associated protein kinase-1 (DAPK) through a lysosome-dependent degradation pathway. FEBS J 278(2):354-370
59. Simonato M, Bennett J, Boulis NM, Castro MG, Fink DJ, Goins WF, Gray SJ, Lowenstein PR, Vandenberghe LH, Wilson TJ, Wolfe JH, Glorioso JC (2013) Progress in gene therapy for neurological disorders. Nat Rev Neurol 9(5):277-291
60. Kay MA (2011) State-of-the-art gene-based therapies: the road ahead. Nat Rev Genet 12(5):316-328
61. Nair SB, Fayaz SM, Rajanikant GK (2013) A novel multi-target drug screening strategy directed against key proteins of DAPK family. Comb Chem High Throughput Screen 16(6):449-457
62. Harrington JA, Wheeler GM, Sweeting MJ, Mander AP, Jodrell DI (2013) Adaptive designs for dual-agent phase I dose-escalation studies. Nat Rev Clin Oncol 10(5):277-288
63. Cohen O, Inbal B, Kissil JL, Raveh T, Berissi H, Spivak-Kroizaman T, Feinstein E, Kimchi A (1999) DAP-kinase participates in TNF-alpha- and Fas-induced apoptosis and its function requires the death domain. J Cell Biol 146(1):141-148
64. Lin Y, Stevens C, Hupp T (2007) Identification of a dominant negative functional domain on DAPK-1 that degrades DAPK-1 protein and stimulates TNFR-1-mediated apoptosis. J biol chem 282(23):16792-16802
65. Jin Y, Blue EK, Gallagher PJ (2006) Control of death-associated protein kinase (DAPK) activity by phosphorylation and proteasomal degradation. J biol chem 281(51):39033-39040
66. Jin Y, Blue EK, Dixon S, Shao Z, Gallagher PJ (2002) A death-associated protein kinase (DAPK)-interacting protein, DIP-1, is an E3 ubiquitin ligase that promotes tumor necrosis factor-induced apoptosis and regulates the cellular levels of DAPK. J biol chem 277(49):46980-46986
67. Lane DP, Cheok CF, Lain S (2010) p53-based cancer therapy. Cold Spring Harb Perspect Biol 2(9):a001222
68. Mandl A, Huong Pham L, Toth K, Zambetti G, Erhardt P (2011) Puma deletion delays cardiac dysfunction in murine heart failure models through attenuation of apoptosis. Circulation 124(1):31-39
69. Takeuchi S, Matsushita M, Zimmermann M, Ikezoe T, Komatsu N, Seriu T, Schrappe M, Bartram CR, Koeffler HP (2011) Clinical significance of aberrant DNA methylation in childhood acute lymphoblastic leukemia. Leuk Res 35(10):1345-1349
70. Roman-Gomez J, Jimenez-Velasco A, Castillejo JA, Agirre X, Barrios M, Navarro G, Molina FJ, Calasanz MJ, Prosper F, Heiniger A, Torres A (2004) Promoter hypermethylation of cancer-related genes: a strong independent prognostic factor in acute lymphoblastic leukemia. Blood 104(8):2492-2498
71. Rossi D, Capello D, Gloghini A, Franceschetti S, Paulli M, Bhatia K, Saglio G, Vitolo U, Pileri SA, Esteller M, Carbone A, Gaidano G (2004) Aberrant promoter methylation of multiple genes throughout the clinico-pathologic spectrum of B-cell neoplasia. Haematologica 89(2):154-164
72. Yang Y, Takeuchi S, Hofmann WK, Ikezoe T, van Dongen JJ, Szczepanski T, Bartram CR, Yoshino N, Taguchi H, Koeffler HP (2006) Aberrant methylation in promoter-associated CpG islands of multiple genes in acute lymphoblastic leukemia. Leuk Res 30(1):98-102
73. Matsushita C, Yang Y, Takeuchi S, Matsushita M, Van Dongen JJ, Szczepanski T, Bartram CR, Seo H, Koeffler HP, Taguchi H (2004) Aberrant methylation in promoter-associated CpG islands of multiple genes in relapsed childhood acute lymphoblastic leukemia. Oncol Rep 12(1):97-99
74. Griffiths EA, Gore SD, Hooker CM, Mohammad HP, McDevitt MA, Smith BD, Karp JE, Herman JG, Carraway HE (2010) Epigenetic differences in cytogenetically normal versus abnormal acute myeloid leukemia. Epigenetics 5(7):590-600
75. Voso MT, Scardocci A, Guidi F, Zini G, Di Mario A, Pagano L, Hohaus S, Leone G (2004) Aberrant methylation of DAP-kinase in therapy-related acute myeloid leukemia and myelodysplastic syndromes. Blood 103(2):698-700
76. Aggerholm A, Hokland P (2000) DAP-kinase CpG island methylation in acute myeloid leukemia: methodology versus biology? Blood 95(9):2997-2999
77. Ekmekci CG, Gutierrez MI, Siraj AK, Ozbek U, Bhatia K (2004) Aberrant methylation of multiple tumor suppressor genes in acute myeloid leukemia. Am J Hematol 77(3):233-240
78. Li J, El-Naggar A, Mao L (2005) Promoter methylation of p16INK4a, RASSF1A, and DAPK is frequent in salivary adenoid cystic carcinoma. Cancer 104(4):771-776
79. Koga Y, Kitajima Y, Miyoshi A, Sato K, Kitahara K, Soejima H, Miyazaki K (2005) Tumor progression through epigenetic gene silencing of O(6)-methylguanine-DNA methyltransferase in human biliary tract cancers. Ann Surg Oncol 12(5):354-363
80. Tozawa T, Tamura G, Honda T, Nawata S, Kimura W, Makino N, Kawata S, Sugai T, Suto T, Motoyama T (2004) Promoter hypermethylation of DAP-kinase is associated with poor survival in primary biliary tract carcinoma patients. Cancer Sci 95(9):736-740
81. Tada Y, Wada M, Taguchi K, Mochida Y, Kinugawa N, Tsuneyoshi M, Naito S, Kuwano M (2002) The association of death-associated protein kinase hypermethylation with early recurrence in superficial bladder cancers. Cancer Res 62(14):4048-4053
82. Maruyama R, Toyooka S, Toyooka KO, Harada K, Virmani AK, Zochbauer-Muller S, Farinas AJ, Vakar-Lopez F, Minna JD, Sagalowsky A, Czerniak B, Gazdar AF (2001) Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. Cancer Res 61(24):8659-8663
83. Gutierrez MI, Siraj AK, Khaled H, Koon N, El-Rifai W, Bhatia K (2004) CpG island methylation in Schistosoma- and non-Schistosoma-associated bladder cancer. Mod Pathol 17(10):1268-1274
84. Christoph F, Weikert S, Kempkensteffen C, Krause H, Schostak M, Miller K, Schrader M (2006) Regularly methylated novel pro-apoptotic genes associated with recurrence in transitional cell carcinoma of the bladder. Int J Cancer 119(6):1396-1402
85. Chen PC, Tsai MH, Yip SK, Jou YC, Ng CF, Chen Y, Wang X, Huang W, Tung CL, Chen GC, Huang MM, Tong JH, Song EJ, Chang DC, Hsu CD, To KF, Shen CH, Chan MW (2011) Distinct DNA methylation epigenotypes in bladder cancer from different Chinese sub-populations and its implication in cancer detection using voided urine. BMC Med Genomics 4:45
86. Chan MW, Chan LW, Tang NL, Tong JH, Lo KW, Lee TL, Cheung HY, Wong WS, Chan PS, Lai FM, To KF (2002) Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients. Clin Cancer Res 8(2):464-470
87. Christoph F, Kempkensteffen C, Weikert S, Kollermann J, Krause H, Miller K, Schostak M, Schrader M (2006) Methylation of tumour suppressor genes APAF-1 and DAPK-1 and in vitro effects of demethylating agents in bladder and kidney cancer. Br J Cancer 95(12):1701-1707
88. Christoph F, Hinz S, Kempkensteffen C, Weikert S, Krause H, Schostak M, Schrader M, Miller K (2007) A gene expression profile of tumor suppressor genes commonly methylated in bladder cancer. J Cancer Res Clin Oncol 133(6):343-349
89. Sobti RC, MalekZadeh K, Nikbakht M, Sadeghi IA, Shekari M, Singh SK (2010) Hypermethylation-mediated partial transcriptional silencing of DAP-kinase gene in bladder cancer. Biomarkers 15(2):167-174
90. Friedrich MG, Chandrasoma S, Siegmund KD, Weisenberger DJ, Cheng JC, Toma MI, Huland H, Jones PA, Liang G (2005) Prognostic relevance of methylation markers in patients with non-muscle invasive bladder carcinoma. Eur J Cancer 41(17):2769-2778
91. Jarmalaite S, Jankevicius F, Kurgonaite K, Suziedelis K, Mutanen P, Husgafvel-Pursiainen K (2008) Promoter hypermethylation in tumour suppressor genes shows association with stage, grade and invasiveness of bladder cancer. Oncology 75(3-4):145-151
92. Van der Auwera I, Bovie C, Svensson C, Limame R, Trinh XB, van Dam P, Van Laere SJ, Van Marck E, Vermeulen PB, Dirix LY (2009) Quantitative assessment of DNA hypermethylation in the inflammatory and non-inflammatory breast cancer phenotypes. Cancer Biol Ther 8(23):2252-2259
93. Van der Auwera I, Bovie C, Svensson C, Trinh XB, Limame R, van Dam P, van Laere SJ, van Marck EA, Dirix LY, Vermeulen PB (2010) Quantitative methylation profiling in tumor and matched morphologically normal tissues from breast cancer patients. BMC Cancer 10:97
94. Lehmann U, Celikkaya G, Hasemeier B, Langer F, Kreipe H (2002) Promoter hypermethylation of the death-associated protein kinase gene in breast cancer is associated with the invasive lobular subtype. Cancer Res 62(22):6634-6638
95. Chu LC, Eberhart CG, Grossman SA, Herman JG (2006) Epigenetic silencing of multiple genes in primary CNS lymphoma. Int J Cancer 119(10):2487-2491
96. Jeong DH, Youm MY, Kim YN, Lee KB, Sung MS, Yoon HK, Kim KT (2006) Promoter methylation of p16, DAPK, CDH1, and TIMP-3 genes in cervical cancer: correlation with clinicopathologic characteristics. Int J Gynecol Cancer 16(3):1234-1240
97. Iliopoulos D, Oikonomou P, Messinis I, Tsezou A (2009) Correlation of promoter hypermethylation in hTERT, DAPK and MGMT genes with cervical oncogenesis progression. Oncol Rep 22(1):199-204
98. Leung RC, Liu SS, Chan KY, Tam KF, Chan KL, Wong LC, Ngan HY (2008) Promoter methylation of death-associated protein kinase and its role in irradiation response in cervical cancer. Oncol Rep 19(5):1339-1345
99. Yang HJ, Liu VW, Wang Y, Chan KY, Tsang PC, Khoo US, Cheung AN, Ngan HY (2004) Detection of hypermethylated genes in tumor and plasma of cervical cancer patients. Gynecol Oncol 93(2):435-440
100. Kang S, Kim JW, Kang GH, Lee S, Park NH, Song YS, Park SY, Kang SB, Lee HP (2006) Comparison of DNA hypermethylation patterns in different types of uterine cancer: cervical squamous cell carcinoma, cervical adenocarcinoma and endometrial adenocarcinoma. Int J Cancer 118(9):2168-2171
101. Narayan G, Arias-Pulido H, Koul S, Vargas H, Zhang FF, Villella J, Schneider A, Terry MB, Mansukhani M, Murty VV (2003) Frequent promoter methylation of CDH1, DAPK, RARB, and HIC1 genes in carcinoma of cervix uteri: its relationship to clinical outcome. Mol Cancer 2:24
102. Yang HJ, Liu VW, Wang Y, Tsang PC, Ngan HY (2006) Differential DNA methylation profiles in gynecological cancers and correlation with clinico-pathological data. BMC Cancer 6:212
103. Zhao XL, Meng ZY, Qiao YH, Zhang HL (2008) Promoter methylation of DAPK gene in cervical carcinoma. Ai Zheng 27(9):919-923
104. Niyazi M, Liu XW, Zhu KC (2012) Death-associated protein kinase promoter (DAPK) hypermethylation in uterine cervical cancer and intraepithelial neoplasia in Uyghur nationality women. Zhonghua Zhong Liu Za Zhi 34(1):31-34
105. Liu XF, Kong FM, Xu Z, Yu SP, Sun FB, Zhang CS, Huang QX, Zhou XT, Song ZW (2007) Promoter hypermethylation of death-associated protein kinase gene in cholangiocarcinoma. Hepatobiliary Pancreat Dis Int 6(4):407-411
106. Yang B, House MG, Guo M, Herman JG, Clark DP (2005) Promoter methylation profiles of tumor suppressor genes in intrahepatic and extrahepatic cholangiocarcinoma. Mod Pathol 18(3):412-420
107. Lee S, Kim WH, Jung HY, Yang MH, Kang GH (2002) Aberrant CpG island methylation of multiple genes in intrahepatic cholangiocarcinoma. Am J Pathol 161(3):1015-1022
108. Raval A, Tanner SM, Byrd JC, Angerman EB, Perko JD, Chen SS, Hackanson B, Grever MR, Lucas DM, Matkovic JJ, Lin TS, Kipps TJ, Murray F, Weisenburger D, Sanger W, Lynch J, Watson P, Jansen M, Yoshinaga Y, Rosenquist R, de Jong PJ, Coggill P, Beck S, Lynch H, de la Chapelle A, Plass C (2007) Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia. Cell 129(5):879-890
109. Satoh A, Toyota M, Itoh F, Kikuchi T, Obata T, Sasaki Y, Suzuki H, Yawata A, Kusano M, Fujita M, Hosokawa M, Yanagihara K, Tokino T, Imai K (2002) DNA methylation and histone deacetylation associated with silencing DAP kinase gene expression in colorectal and gastric cancers. Br J Cancer 86(11):1817-1823
110. Schneider-Stock R, Kuester D, Ullrich O, Mittag F, Habold C, Boltze C, Peters B, Krueger S, Hintze C, Meyer F, Hartig R, Roessner A (2006) Close localization of DAP-kinase positive tumour-associated macrophages and apoptotic colorectal cancer cells. J Pathol 209(1):95-105
111. Lee S, Hwang KS, Lee HJ, Kim JS, Kang GH (2004) Aberrant CpG island hypermethylation of multiple genes in colorectal neoplasia. Lab Invest 84(7):884-893
112. Lee BB, Lee EJ, Jung EH, Chun HK, Chang DK, Song SY, Park J, Kim DH (2009) Aberrant methylation of APC, MGMT, RASSF2A, and Wif-1 genes in plasma as a biomarker for early detection of colorectal cancer. Clin Cancer Res 15(19):6185-6191
113. Anacleto C, Leopoldino AM, Rossi B, Soares FA, Lopes A, Rocha JC, Caballero O, Camargo AA, Simpson AJ, Pena SD (2005) Colorectal cancer "methylator phenotype": fact or artifact? Neoplasia 7(4):331-335
114. Iacopetta B, Grieu F, Li W, Ruszkiewicz A, Caruso M, Moore J, Watanabe G, Kawakami K (2006) APC gene methylation is inversely correlated with features of the CpG island methylator phenotype in colorectal cancer. Int J Cancer 119(10):2272-2278
115. Yamaguchi S, Asao T, Nakamura J, Ide M, Kuwano H (2003) High frequency of DAP-kinase gene promoter methylation in colorectal cancer specimens and its identification in serum. Cancer Lett 194(1):99-105
116. Anacleto C, Rossi B, Lopes A, Soares FA, Rocha JC, Caballero O, Camargo AA, Simpson AJ, Pena SD (2005) Development and application of a multiplex PCR procedure for the detection of DNA methylation in colorectal cancer. Oncol Rep 13(2):325-328
117. Mittag F, Kuester D, Vieth M, Peters B, Stolte B, Roessner A, Schneider-Stock R (2006) DAPK promotor methylation is an early event in colorectal carcinogenesis. Cancer Lett 240(1):69-75
118. Hoon DS, Spugnardi M, Kuo C, Huang SK, Morton DL, Taback B (2004) Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients. Oncogene 23(22):4014-4022
119. Nakamichi I, Tomita Y, Zhang B, Sugiyama H, Kanakura Y, Fukuhara S, Hino M, Kanamaru A, Ogawa H, Aozasa K (2007) Correlation between promoter hypermethylation of GSTP1 and response to chemotherapy in diffuse large B cell lymphoma. Ann Hematol 86(8):557-564
120. Amara K, Trimeche M, Ziadi S, Laatiri A, Hachana M, Korbi S (2008) Prognostic significance of aberrant promoter hypermethylation of CpG islands in patients with diffuse large B-cell lymphomas. Ann Oncol 19(10):1774-1786
121. Nakatsuka S, Takakuwa T, Tomita Y, Hoshida Y, Nishiu M, Yamaguchi M, Nishii K, Yang WI, Aozasa K (2003) Hypermethylation of death-associated protein (DAP) kinase CpG island is frequent not only in B-cell but also in T- and natural killer (NK)/T-cell malignancies. Cancer Sci 94(1):87-91
122. Brock MV, Gou M, Akiyama Y, Muller A, Wu TT, Montgomery E, Deasel M, Germonpre P, Rubinson L, Heitmiller RF, Yang SC, Forastiere AA, Baylin SB, Herman JG (2003) Prognostic importance of promoter hypermethylation of multiple genes in esophageal adenocarcinoma. Clin Cancer Res 9(8):2912-2919
123. Li B, Wang B, Niu LJ, Jiang L, Qiu CC (2011) Hypermethylation of multiple tumor-related genes associated with DNMT3b up-regulation served as a biomarker for early diagnosis of esophageal squamous cell carcinoma. Epigenetics 6(3):307-316
124. Kuester D, Dar AA, Moskaluk CC, Krueger S, Meyer F, Hartig R, Stolte M, Malfertheiner P, Lippert H, Roessner A, El-Rifai W, Schneider-Stock R (2007) Early involvement of death-associated protein kinase promoter hypermethylation in the carcinogenesis of Barrett's esophageal adenocarcinoma and its association with clinical progression. Neoplasia 9(3):236-245
125. Schildhaus HU, Krockel I, Lippert H, Malfertheiner P, Roessner A, Schneider-Stock R (2005) Promoter hypermethylation of p16INK4a, E-cadherin, O6-MGMT, DAPK and FHIT in adenocarcinomas of the esophagus, esophagogastric junction and proximal stomach. Int J Oncol 26(6):1493-1500
126. Voso MT, Gumiero D, D'Alo F, Guidi F, Mansueto G, Di Febo AL, Massini G, Martini M, Larocca LM, Hohaus S, Leone G (2006) DAP-kinase hypermethylation in the bone marrow of patients with follicular lymphoma. Haematologica 91(9):1252-1256
127. Krajnovic M, Radojkovic M, Davidovic R, Dimitrijevic B, Krtolica K (2013) Prognostic significance of epigenetic inactivation of p16, p15, MGMT and DAPK genes in follicular lymphoma. Med Oncol 30(1):441
128. Kim HC, Kim JC, Roh SA, Yu CS, Yook JH, Oh ST, Kim BS, Park KC, Chang R (2005) Aberrant CpG island methylation in early-onset sporadic gastric carcinoma. J Cancer Res Clin Oncol 131(11):733-740
129. To KF, Leung WK, Lee TL, Yu J, Tong JH, Chan MW, Ng EK, Chung SC, Sung JJ (2002) Promoter hypermethylation of tumor-related genes in gastric intestinal metaplasia of patients with and without gastric cancer. Int J Cancer 102(6):623-628
130. Kato K, Iida S, Uetake H, Takagi Y, Yamashita T, Inokuchi M, Yamada H, Kojima K, Sugihara K (2008) Methylated TMS1 and DAPK genes predict prognosis and response to chemotherapy in gastric cancer. Int J Cancer 122(3):603-608
131. Kang GH, Shim YH, Jung HY, Kim WH, Ro JY, Rhyu MG (2001) CpG island methylation in premalignant stages of gastric carcinoma. Cancer Res 61(7):2847-2851
132. Lee TL, Leung WK, Chan MW, Ng EK, Tong JH, Lo KW, Chung SC, Sung JJ, To KF (2002) Detection of gene promoter hypermethylation in the tumor and serum of patients with gastric carcinoma. Clin Cancer Res 8(6):1761-1766
133. Tang LP, Cho CH, Hui WM, Huang C, Chu KM, Xia HH, Lam SK, Rashid A, Wong BC, Chan AO (2006) An inverse correlation between Interleukin-6 and select gene promoter methylation in patients with gastric cancer. Digestion 74(2):85-90
134. Tahara T, Shibata T, Nakamura M, Yamashita H, Yoshioka D, Okubo M, Yonemura J, Maeda Y, Maruyama N, Kamano T, Kamiya Y, Fujita H, Nakagawa Y, Nagasaka M, Iwata M, Hirata I, Arisawa T (2010) Association between cyclin D1 polymorphism with CpG island promoter methylation status of tumor suppressor genes in gastric cancer. Dig Dis Sci 55(12):3449-3457
135. Ksiaa F, Ziadi S, Amara K, Korbi S, Trimeche M (2009) Biological significance of promoter hypermethylation of tumor-related genes in patients with gastric carcinoma. Clin Chim Acta 404(2):128-133
136. Ye M, Li D, Zhou F, Guo Q, Xia B (2012) Epigenetic regulation of death-associated protein kinase expression in primary gastric cancers from Chinese patients. Eur J Cancer Prev 21(3):241-246
137. Ben Ayed-Guerfali D, Benhaj K, Khabir A, Abid M, Bayrouti MI, Sellami-Boudawara T, Gargouri A, Mokdad-Gargouri R (2011) Hypermethylation of tumor-related genes in Tunisian patients with gastric carcinoma: clinical and biological significance. J Surg Oncol 103(7):687-694
138. Chan AW, Chan MW, Lee TL, Ng EK, Leung WK, Lau JY, Tong JH, Chan FK, To KF (2005) Promoter hypermethylation of death-associated protein-kinase gene associated with advance stage gastric cancer. Oncol Rep 13(5):937-941
139. Gao Y, Guan M, Su B, Liu W, Xu M, Lu Y (2004) Hypermethylation of the RASSF1A gene in gliomas. Clin Chim Acta 349(1-2):173-179
140. Hasegawa M, Nelson HH, Peters E, Ringstrom E, Posner M, Kelsey KT (2002) Patterns of gene promoter methylation in squamous cell cancer of the head and neck. Oncogene 21(27):4231-4236
141. Nayak CS, Carvalho AL, Jeronimo C, Henrique R, Kim MM, Hoque MO, Chang S, Jiang WW, Koch W, Westra W, Sidransky D, Califano J (2007) Positive correlation of tissue inhibitor of metalloproteinase-3 and death-associated protein kinase hypermethylation in head and neck squamous cell carcinoma. Laryngoscope 117(8):1376-1380
142. Maruya S, Issa JP, Weber RS, Rosenthal DI, Haviland JC, Lotan R, El-Naggar AK (2004) Differential methylation status of tumor-associated genes in head and neck squamous carcinoma: incidence and potential implications. Clin Cancer Res 10(11):3825-3830
143. Martone T, Gillio-Tos A, De Marco L, Fiano V, Maule M, Cavalot A, Garzaro M, Merletti F, Cortesina G (2007) Association between hypermethylated tumor and paired surgical margins in head and neck squamous cell carcinomas. Clin Cancer Res 13(17):5089-5094
144. Sanchez-Cespedes M, Esteller M, Wu L, Nawroz-Danish H, Yoo GH, Koch WM, Jen J, Herman JG, Sidransky D (2000) Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Res 60(4):892-895
145. Rosas SL, Koch W, da Costa Carvalho MG, Wu L, Califano J, Westra W, Jen J, Sidransky D (2001) Promoter hypermethylation patterns of p16, O6-methylguanine-DNA-methyltransferase, and death-associated protein kinase in tumors and saliva of head and neck cancer patients. Cancer Res 61(3):939-942
146. Lehmann U, Berg-Ribbe I, Wingen LU, Brakensiek K, Becker T, Klempnauer J, Schlegelberger B, Kreipe H, Flemming P (2005) Distinct methylation patterns of benign and malignant liver tumors revealed by quantitative methylation profiling. Clin Cancer Res 11(10):3654-3660
147. Nomoto S, Kinoshita T, Kato K, Otani S, Kasuya H, Takeda S, Kanazumi N, Sugimoto H, Nakao A (2007) Hypermethylation of multiple genes as clonal markers in multicentric hepatocellular carcinoma. Br J Cancer 97(9):1260-1265
148. Harder J, Opitz OG, Brabender J, Olschewski M, Blum HE, Nomoto S, Usadel H (2008) Quantitative promoter methylation analysis of hepatocellular carcinoma, cirrhotic and normal liver. Int J Cancer 122(12):2800-2804
149. Dikshit RP, Gillio-Tos A, Brennan P, De Marco L, Fiano V, Martinez-Penuela JM, Boffetta P, Merletti F (2007) Hypermethylation, risk factors, clinical characteristics, and survival in 235 patients with laryngeal and hypopharyngeal cancers. Cancer 110(8):1745-1751
150. Kong WJ, Zhang S, Guo C, Wang Y, Zhang D (2005) Methylation-associated silencing of death-associated protein kinase gene in laryngeal squamous cell cancer. Laryngoscope 115(8):1395-1401
151. Paluszczak J, Misiak P, Wierzbicka M, Wozniak A, Baer-Dubowska W (2011) Frequent hypermethylation of DAPK, RARbeta, MGMT, RASSF1A and FHIT in laryngeal squamous cell carcinomas and adjacent normal mucosa. Oral Oncol 47(2):104-107
152. Niklinska W, Naumnik W, Sulewska A, Kozlowski M, Pankiewicz W, Milewski R (2009) Prognostic significance of DAPK and RASSF1A promoter hypermethylation in non-small cell lung cancer (NSCLC). Folia Histochem Cytobiol 47(2):275-280
153. Wang Y, Zhang D, Zheng W, Luo J, Bai Y, Lu Z (2008) Multiple gene methylation of nonsmall cell lung cancers evaluated with 3-dimensional microarray. Cancer 112(6):1325-1336
154. Kim DH, Nelson HH, Wiencke JK, Christiani DC, Wain JC, Mark EJ, Kelsey KT (2001) Promoter methylation of DAP-kinase: association with advanced stage in non-small cell lung cancer. Oncogene 20(14):1765-1770
155. Zochbauer-Muller S, Fong KM, Virmani AK, Geradts J, Gazdar AF, Minna JD (2001) Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res 61(1):249-255
156. Safar AM, Spencer H 3rd, Su X, Coffey M, Cooney CA, Ratnasinghe LD, Hutchins LF, Fan CY (2005) Methylation profiling of archived non-small cell lung cancer: a promising prognostic system. Clin Cancer Res 11(12):4400-4405
157. Yanagawa N, Tamura G, Oizumi H, Takahashi N, Shimazaki Y, Motoyama T (2003) Promoter hypermethylation of tumor suppressor and tumor-related genes in non-small cell lung cancers. Cancer Sci 94(7):589-592
158. Shivapurkar N, Stastny V, Suzuki M, Wistuba II, Li L, Zheng Y, Feng Z, Hol B, Prinsen C, Thunnissen FB, Gazdar AF (2007) Application of a methylation gene panel by quantitative PCR for lung cancers. Cancer Lett 247(1):56-71
159. Kim YT, Lee SH, Sung SW, Kim JH (2005) Can aberrant promoter hypermethylation of CpG islands predict the clinical outcome of non-small cell lung cancer after curative resection? Ann Thorac Surg 79(4):1180-1188 Discussion 1180-1188
160. Vallbohmer D, Brabender J, Yang D, Schneider PM, Metzger R, Danenberg KD, Holscher AH, Danenberg PV (2006) DNA methyltransferases messenger RNA expression and aberrant methylation of CpG islands in non-small-cell lung cancer: association and prognostic value. Clin Lung Cancer 8(1):39-44
161. Yanagawa N, Tamura G, Oizumi H, Kanauchi N, Endoh M, Sadahiro M, Motoyama T (2007) Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers. Lung Cancer 58(1):131-138
162. Tang X, Khuri FR, Lee JJ, Kemp BL, Liu D, Hong WK, Mao L (2000) Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage I non-small-cell lung cancer. J Natl Cancer Inst 92(18):1511-1516
163. Rastetter M, Schagdarsurengin U, Lahtz C, Fiedler E, Marsch W, Dammann R, Helmbold P (2007) Frequent intra-tumoural heterogeneity of promoter hypermethylation in malignant melanoma. Histol Histopathol 22(9):1005-1015
164. Fischer JR, Ohnmacht U, Rieger N, Zemaitis M, Stoffregen C, Kostrzewa M, Buchholz E, Manegold C, Lahm H (2006) Promoter methylation of RASSF1A, RARbeta and DAPK predict poor prognosis of patients with malignant mesothelioma. Lung Cancer 54(1):109-116
165. Chim CS, Liang R, Leung MH, Kwong YL (2007) Aberrant gene methylation implicated in the progression of monoclonal gammopathy of undetermined significance to multiple myeloma. J Clin Pathol 60(1):104-106
166. Chim CS, Liang R, Fung TK, Choi CL, Kwong YL (2007) Epigenetic dysregulation of the death-associated protein kinase/p14/HDM2/p53/Apaf-1 apoptosis pathway in multiple myeloma. J Clin Pathol 60(6):664-669
167. Ng MH, To KW, Lo KW, Chan S, Tsang KS, Cheng SH, Ng HK (2001) Frequent death-associated protein kinase promoter hypermethylation in multiple myeloma. Clin Cancer Res 7(6):1724-1729
168. Yuregir OO, Yurtcu E, Kizilkilic E, Kocer NE, Ozdogu H, Sahin FI (2010) Detecting methylation patterns of p16, MGMT, DAPK and E-cadherin genes in multiple myeloma patients. Int J Lab Hematol 32(2):142-149
169. Braggio E, Maiolino A, Gouveia ME, Magalhaes R, Souto Filho JT, Garnica M, Nucci M, Renault IZ (2010) Methylation status of nine tumor suppressor genes in multiple myeloma. Int J Hematol 91(1):87-96
170. Kwong J, Lo KW, To KF, Teo PM, Johnson PJ, Huang DP (2002) Promoter hypermethylation of multiple genes in nasopharyngeal carcinoma. Clin Cancer Res 8(1):131-137
171. Wong TS, Chang HW, Tang KC, Wei WI, Kwong DL, Sham JS, Yuen AP, Kwong YL (2002) High frequency of promoter hypermethylation of the death-associated protein-kinase gene in nasopharyngeal carcinoma and its detection in the peripheral blood of patients. Clin Cancer Res 8(2):433-437
172. Fendri A, Masmoudi A, Khabir A, Sellami-Boudawara T, Daoud J, Frikha M, Ghorbel A, Gargouri A, Mokdad-Gargouri R (2009) Inactivation of RASSF1A, RARbeta2 and DAP-kinase by promoter methylation correlates with lymph node metastasis in nasopharyngeal carcinoma. Cancer Biol Ther 8(5):444-451
173. Kong WJ, Zhang S, Guo CK, Wang YJ, Chen X, Zhang SL, Zhang D, Liu Z, Kong W (2006) Effect of methylation-associated silencing of the death-associated protein kinase gene on nasopharyngeal carcinoma. Anticancer Drugs 17(3):251-259
174. Challouf S, Ziadi S, Zaghdoudi R, Ksiaa F, Ben Gacem R, Trimeche M (2012) Patterns of aberrant DNA hypermethylation in nasopharyngeal carcinoma in Tunisian patients. Clin Chim Acta 413(7-8):795-802
175. Gonzalez-Gomez P, Bello MJ, Arjona D, Alonso ME, Lomas J, De Campos JM, Kusak ME, Gutierrez M, Sarasa JL, Rey JA (2003) Aberrant CpG island methylation in neurofibromas and neurofibrosarcomas. Oncol Rep 10(5):1519-1523
176. Choung HK, Kim YA, Lee MJ, Kim N, Khwarg SI (2012) Multigene methylation analysis of ocular adnexal MALT lymphoma and their relationship to Chlamydophila psittaci infection and clinical characteristics in South Korea. Invest Ophthalmol Vis Sci 53(4):1928-1935
177. Ishii T, Murakami J, Notohara K, Cullings HM, Sasamoto H, Kambara T, Shirakawa Y, Naomoto Y, Ouchida M, Shimizu K, Tanaka N, Jass JR, Matsubara N (2007) Oesophageal squamous cell carcinoma may develop within a background of accumulating DNA methylation in normal and dysplastic mucosa. Gut 56(1):13-19
178. Ogi K, Toyota M, Ohe-Toyota M, Tanaka N, Noguchi M, Sonoda T, Kohama G, Tokino T (2002) Aberrant methylation of multiple genes and clinicopathological features in oral squamous cell carcinoma. Clin Cancer Res 8(10):3164-3171
179. Liu Y, Zhou ZT, He QB, Jiang WW (2012) DAPK promoter hypermethylation in tissues and body fluids of oral precancer patients. Med Oncol 29(2):729-733
180. Supic G, Kozomara R, Brankovic-Magic M, Jovic N, Magic Z (2009) Gene hypermethylation in tumor tissue of advanced oral squamous cell carcinoma patients. Oral Oncol 45(12):1051-1057
181. Teodoridis JM, Hall J, Marsh S, Kannall HD, Smyth C, Curto J, Siddiqui N, Gabra H, McLeod HL, Strathdee G, Brown R (2005) CpG island methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res 65(19):8961-8967
182. Hafner N, Diebolder H, Jansen L, Hoppe I, Durst M, Runnebaum IB (2011) Hypermethylated DAPK in serum DNA of women with uterine leiomyoma is a biomarker not restricted to cancer. Gynecol Oncol 121(1):224-229
183. Collins Y, Dicioccio R, Keitz B, Lele S, Odunsi K (2006) Methylation of death-associated protein kinase in ovarian carcinomas. Int J Gynecol Cancer 16(Suppl 1):195-199
184. Peng DF, Kanai Y, Sawada M, Ushijima S, Hiraoka N, Kitazawa S, Hirohashi S (2006) DNA methylation of multiple tumor-related genes in association with overexpression of DNA methyltransferase 1 (DNMT1) during multistage carcinogenesis of the pancreas. Carcinogenesis 27(6):1160-1168
185. Dansranjavin T, Mobius C, Tannapfel A, Bartels M, Wittekind C, Hauss J, Witzigmann H (2006) E-cadherin and DAP kinase in pancreatic adenocarcinoma and corresponding lymph node metastases. Oncol Rep 15(5):1125-1131
186. Yamanaka M, Watanabe M, Yamada Y, Takagi A, Murata T, Takahashi H, Suzuki H, Ito H, Tsukino H, Katoh T, Sugimura Y, Shiraishi T (2003) Altered methylation of multiple genes in carcinogenesis of the prostate. Int J Cancer 106(3):382-387
187. Maruyama R, Toyooka S, Toyooka KO, Virmani AK, Zochbauer-Muller S, Farinas AJ, Minna JD, McConnell J, Frenkel EP, Gazdar AF (2002) Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Clin Cancer Res 8(2):514-519
188. Yegnasubramanian S, Kowalski J, Gonzalgo ML, Zahurak M, Piantadosi S, Walsh PC, Bova GS, De Marzo AM, Isaacs WB, Nelson WG (2004) Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res 64(6):1975-1986
189. Morris MR, Hesson LB, Wagner KJ, Morgan NV, Astuti D, Lees RD, Cooper WN, Lee J, Gentle D, Macdonald F, Kishida T, Grundy R, Yao M, Latif F, Maher ER (2003) Multigene methylation analysis of Wilms' tumour and adult renal cell carcinoma. Oncogene 22(43):6794-6801
190. Christoph F, Weikert S, Kempkensteffen C, Krause H, Schostak M, Kollermann J, Miller K, Schrader M (2006) Promoter hypermethylation profile of kidney cancer with new proapoptotic p53 target genes and clinical implications. Clin Cancer Res 12(17):5040-5046
191. Ahmad ST, Arjumand W, Seth A, Saini AK, Sultana S (2012) Methylation of the APAF-1 and DAPK-1 promoter region correlates with progression of renal cell carcinoma in North Indian population. Tumour Biol 33(2):395-402
192. Sato H, Oka T, Shinnou Y, Kondo T, Washio K, Takano M, Takata K, Morito T, Huang X, Tamura M, Kitamura Y, Ohara N, Ouchida M, Ohshima K, Shimizu K, Tanimoto M, Takahashi K, Matsuoka M, Utsunomiya A, Yoshino T (2010) Multi-step aberrant CpG island hyper-methylation is associated with the progression of adult T-cell leukemia/lymphoma. Am J Pathol 176(1):402-415
193. Brait M, Loyo M, Rosenbaum E, Ostrow KL, Markova A, Papagerakis S, Zahurak M, Goodman SM, Zeiger M, Sidransky D, Umbricht CB, Hoque MO (2012) Correlation between BRAF mutation and promoter methylation of TIMP3, RARbeta2 and RASSF1A in thyroid cancer. Epigenetics 7(7):710-719
194. Schagdarsurengin U, Gimm O, Dralle H, Hoang-Vu C, Dammann R (2006) CpG island methylation of tumor-related promoters occurs preferentially in undifferentiated carcinoma. Thyroid 16(7):633-642
195. Su Y, Xu H, Xu Y, Yu J, Xian Y, Luo Q (2012) Azacytidine inhibits the proliferation of human promyelocytic leukemia cells (HL60) by demethylation of MGMT, DAPK and p16 genes. Hematology 17(1):41-46
196. Ling YH, Aracil M, Zou Y, Yuan Z, Lu B, Jimeno J, Cuervo AM, Perez-Soler R (2011) PM02734 (elisidepsin) induces caspase-independent cell death associated with features of autophagy, inhibition of the Akt/mTOR signaling pathway, and activation of death-associated protein kinase. Clin Cancer Res 17(16):5353-5366
197. Luo XJ, Li LL, Deng QP, Yu XF, Yang LF, Luo FJ, Xiao LB, Chen XY, Ye M, Liu JK, Cao Y (2011) Grifolin, a potent antitumour natural product upregulates death-associated protein kinase 1 DAPK1 via p53 in nasopharyngeal carcinoma cells. Eur J Cancer 47(2):316-325
198. Zhang H, Chen GG, Zhang Z, Chun S, Leung BC, Lai PB (2012) Induction of autophagy in hepatocellular carcinoma cells by SB203580 requires activation of AMPK and DAPK but not p38 MAPK. Apoptosis 17(4):325-334
199. Shin H, Lee YS, Lee YC (2012) Sodium butyrate-induced DAPK-mediated apoptosis in human gastric cancer cells. Oncol Rep 27(4):1111-1115
200. Zhang HT, Feng ZL, Wu J, Wang YJ, Guo X, Liang NC, Zhu ZY, Ma JQ (2007) Sodium butyrate-induced death-associated protein kinase expression promote Raji cell morphological change and apoptosis by reducing FAK protein levels. Acta Pharmacol Sin 28(11):1783-1790
201. Jiang Q, Li F, Shi K, Yang Y, Xu C (2012) Sodium selenite-induced activation of DAPK promotes autophagy in human leukemia HL60 cells. BMB Rep 45(3):194-199
202. Wu J, Hu CP, Gu QH, Li YP, Song M (2010) Trichostatin A sensitizes cisplatin-resistant A549 cells to apoptosis by up-regulating death-associated protein kinase. Acta Pharmacol Sin 31(1):93-101
203. Ivanovska J, Tregubova A, Mahadevan V, Chakilam S, Gandesiri M, Benderska N, Ettle B, Hartmann A, Soder S, Ziesche E, Fischer T, Lautscham L, Fabry B, Segerer G, Gohla A, Schneider-Stock R (2013) Identification of DAPK as a scaffold protein for the LIMK/cofilin complex in TNF-induced apoptosis. Int J Biochem Cell Biol 45(8):1720-1729